OSR Holdings moves towards major licensing deal for oral cancer immunotherapy
Under the proposed terms, Vaximm would secure a $20 million upfront payment, up to $815 million tied to clinical, regulatory, and commercial milestones
Under the proposed terms, Vaximm would secure a $20 million upfront payment, up to $815 million tied to clinical, regulatory, and commercial milestones
Phase one of the expansion will convert an existing hall into an ISO 7-certified cleanroom for GMP-compliant production
The oral, film-coated tablet is licensed for patients whose cancer has returned during or shortly after hormone therapy
Soficitinib is a potent and selective TYK2 inhibitor under development for multiple T-cell mediated autoimmune disorders
Nitrosamines have prompted evolving global guidelines that demand rigorous industry oversight
The fresh capital will propel Cordance into its first-in-human clinical trial
Clinical studies conducted in India demonstrated that this nebulized triple therapy rapidly improves lung function and offers better control of breathlessness
India's pharmaceutical sector is rapidly shifting from a generics-led foundation to an innovation-driven ecosystem
The approval by the US FDA comes after extensive safety testing and manufacturing improvements
Subscribe To Our Newsletter & Stay Updated